ALS Longitude Prize Judges

An international panel will judge the Longitude Prize on Amyotrophic lateral sclerosis (ALS), a five-year, £7.5 million effort to use AI to speed drug discovery. The panel includes top scientists and industry leaders, with a patient advocate as chair. Entries run June–December 2025. From 2026–2031, teams receive staged funding: 20 teams £100,000, 10 teams £200,000, 5 teams £500,000, and one winner £1,000,000.